Protagonist Therapeutics PTGX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's investment proceeds?
- Protagonist Therapeutics (PTGX) reported investment proceeds of $156.69M in Q1 2026.
- How has Protagonist Therapeutics's investment proceeds changed year-over-year?
- Protagonist Therapeutics's investment proceeds increased by 38.4% year-over-year, from $113.18M to $156.69M.
- What is the long-term trend for Protagonist Therapeutics's investment proceeds?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's investment proceeds has grown at a 16.0% compound annual growth rate (CAGR), from $271.83M to $491.84M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.